Fig. 3

Time to first outcome by index treatment and prior biologic exposure. Kaplan-Meier time to first outcome in patients with ulcerative colitis (panels a-c) or Crohn’s disease (panels d-f) by index treatment (vedolizumab vs anti-tumor necrosis factor alpha [anti-TNFα]) and prior biologic exposure (biologic-naïve vs one previous anti-TNFα agent)